Says profit adjustment takes account of around $400M that is expected to be incurred in J&J’s medtech business due to tariffs currently in place, including those on China and Mexico.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Morning Movers: Boeing slips as latest victim of trade war
- Johnson & Johnson says ‘continues to be excited’ about icotrokinra potential
- Johnson & Johnson says ‘strong start’ to 2025
- Options Volatility and Implied Earnings Moves Today, April 15, 2025
- Johnson & Johnson provides 2027/2028 sales view of Innovative Medicine assets